Institutional members access full text with Ovid®

Share this article on:

Trans-catheter mitral valve implantation for mitral regurgitation: clinical case description and literature review

Romeo, Francesco; Cammalleri, Valeria; Ruvolo, Giovanni; Quadri, Arshad; De Vico, Pasquale; Muscoli, Saverio; Marchei, Massimo; Meloni, Sabrina; Conti, Fabio; Ussia, Gian Paolo

Journal of Cardiovascular Medicine: February 2016 - Volume 17 - Issue 2 - p 85–91
doi: 10.2459/JCM.0000000000000328
Reviews

Trans-catheter mitral valve implantation (TMVI) is actually the most attractive technique for treating patients with severe mitral regurgitation, who are denied surgical therapy. Recently, trans-catheter implantation of aortic biological prosthesis in mitral position has been done in compassionate cases, and very few experiences of TMVI in native non-calcified valves have been recently reported in very-high-risk patients, mainly with functional mitral regurgitation.

Here, we report our case of TMVI using the second-generation CardiAQ prostheisis (CardiAQ Valve Technologies, Irvine, California, USA), reviewing the current state of the art.

aDepartment of Cardiovascular Disease

bDepartment of Cardiac Surgery, University of Rome ‘Tor Vergata’, Rome, Italy

cDepartment of Cardiac Surgery, St Francis Hospital, Hartford, Connecticut, USA

dDepartment of Anaesthesia, University of Rome ‘Tor Vergata’, Rome, Italy

Correspondence to Gian Paolo Ussia, MD, Department of Cardiovascular Disease, University of Rome ‘Tor Vergata’, Rome, Viale Oxford, 81 00133 Rome, ItalyTel: +39 06 20904009; fax: +39 06 20904008; e-mail: gianpaolo.ussia@uniroma2.it

Received 11 June, 2015

Revised 23 September, 2015

Accepted 23 September, 2015

© 2016 Italian Federation of Cardiology. All rights reserved.